Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Bavarian Nordic board backs higher bid amid shareholder holdout
16 Oct 2025, 05:28BAVA.CONASDAQ Copenhagen

Bavarian Nordic's board of directors on Thursday reiterated its recommendation for shareholders to accept a takeover offer from a private equity consortium led by Nordic Capital and Permira.

Private equity raises Bavarian Nordic bid, faces shareholder test
15 Oct 2025, 15:59BAVA.CONASDAQ Copenhagen

A private equity consortium led by Nordic Capital and Permira has raised its takeover bid for Danish vaccine maker Bavarian Nordic to 250 Danish Krone per share from 233 Danish Krone.

Nordic Capital, Permira clear final hurdle for Bavarian Nordic takeover
9 Oct 2025, 12:24BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has received the final regulatory approval needed for its proposed takeover of Danish vaccine maker Bavarian Nordic.

Bavarian Nordic's mpox vaccine shows strong results in children
7 Oct 2025, 14:59BAVA.CONASDAQ Copenhagen

Bavarian Nordic said Tuesday its mpox and smallpox vaccine produced a strong immune response and was well-tolerated in children aged 2 to 11 in a clinical study.

Bavarian Nordic posts strong results ahead of PE buyout
22 Aug 2025, 05:38BAVA.CONASDAQ Copenhagen

Danish vaccine maker Bavarian Nordic on Friday reported a 33% rise in first-half revenue, posting strong results as it prepares for a takeover by a private equity consortium.

Bavarian Nordic agrees to DKK 19 billion takeover offer
6 Aug 2025, 20:30BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has agreed to acquire Danish vaccine maker Bavarian Nordic in an all-cash deal valuing the company at approximately 19 billion Danish Krone.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Bavarian Nordic A/S - Articles of Association30 Apr 2018
Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held April 17, 201817 Apr 2018
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting26 Mar 2018
Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus16 Mar 2018
Bavarian Nordic Awards Restricted Stock Units to Executive Management12 Mar 2018
Bavarian Nordic Announces Annual Report 201712 Mar 2018
Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer8 Mar 2018
Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine6 Mar 2018
Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers26 Feb 2018
Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine6 Feb 2018
Bavarian Nordic Announces the Planned Departure of Chief Financial Officer, Ole Larsen31 Jan 2018
Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis19 Jan 2018
  • Previous
  • 1
  • More pages
  • 28
Search
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
  • 3
  • Next
  • 29
  • 30
  • More pages
  • 78
  • Next
  • Filings
    927